Universitätsklinikum Göttingen

Association of an initial Exanthem with Vemurafenib and Cobimetinib for a better Therapeutic Success in metastatic Melanoma Patients (2019) Kaehler K, Bohne AS, Gutzmer R, Satzger I, Meier F, Reinhardt L, Zimmer L, et al. Conference contribution Lipase Elevations and Diabetes under Checkpoint Inhibition - Experience in 80 Patients (2019) Weihkopf D, Satzger I, Zimmer L, Eigentler T, Haessel J, Heinzerling L, Herbst R, et al. Conference contribution Characterization of Patients with inoperable malignant Stage IIIB-D Melanoma (2019) Zaremba A, Weishaupt C, Glutsch V, Schilling B, Loquai C, Rafei-Shamsabadi D, Meiss F, et al. Conference contribution The German National Registry of Primary Immunodeficiencies (2012-2017) (2019) El-Helou SM, Biegner AK, Bode S, Ehl SR, Heeg M, Maccari ME, Ritterbusch H, et al. Journal article Epigenetic regulation in myelinating glia: the role of histone 2b monoubiquitination in Schwann cells (2019) Wüst H, Wegener A, Johnson S, Fröb F, Wegner M, Sock E Conference contribution Mutations in the BAF-complex subunit DPF2 are associated with Coffin-Siris syndrome (2019) Vasileiou G, Vergarajauregui S, Endele S, Popp B, Büttner C, Ekici AB, Gerard M, et al. Conference contribution Randomized phase 2 trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12 (2019) Hofheinz R, Fokas E, Allgaeuer M, Polat B, Klautke G, Grabenbauer G, Fietkau R, et al. Conference contribution Nephroprotective treatment exemplified by Alport syndome (2019) Gross O, Rascher W Journal article Favorable radiation field decrease in gastric marginal zone lymphoma Experience of the German Study Group on Gastrointestinal Lymphoma (DSGL) (2019) Reinartz G, Pyra RP, Lenz G, Liersch R, Stueben G, Micke O, Willborn K, et al. Journal article Chemoradiotherapy plus induction versus consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-12 multicentre, open-label, randomised, phase 2 trial (2019) Fokas E, Allgaeuer M, Polat B, Klautke G, Grabenbauer G, Fietkau R, Kuhnt T, et al. Conference contribution